Jyong Biotech Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Filing of Annual Report on Form 20-F for Fiscal Year 2026 | 15 May 2027 |
Monitoring Framework
Key Performance Indicators
Clinical Trial Progress of MCS-2 (Botreso) QuarterlyTarget: FDA NDA acceptance and comparability approval between API-1 and API-2
MCS-8 (PCP) Phase II Clinical Trial Milestones QuarterlyTarget: Completion of Phase II statistical analysis and preparation for Phase III
Cash and Cash Equivalents Quarterly1.2MTarget: Sufficient capital to sustain ongoing clinical operations and satisfy legal liabilities
Accrued Liabilities and Legal Obligations Annually25.1MTarget: Resolution and settlement of the Taizhou investment dispute and related liabilities
Watch Items
- FDA Comparability Assessment for Botreso (MCS-2)Trigger: FDA rejection of comparability between API-1 and API-2Action: Re-evaluate clinical trial timeline; prepare to repeat Phase III and PK studies using API-2.
- Taizhou Investment Dispute SettlementTrigger: Enforcement of the USD 19.4 million joint liability judgmentAction: Assess impact on cash runway; negotiate payment terms or seek additional equity/debt financing.
- Going Concern StatusTrigger: Inability to secure additional funding within 12 monthsAction: Implement cost-reduction measures, prioritize core pipeline assets, or seek strategic co-development partnerships.
Research as of 20 Jun 2026